This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Selecta's (SELB) Gene Therapy Gets Orphan Drug Tag From FDA
by Zacks Equity Research
The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Disease tag.
Selecta's (SELB) Q3 Loss Narrower-Than Expected, Revenues Beat
by Zacks Equity Research
Selecta (SELB) beat estimates for both earnings and revenues in the third quarter of 2020.
What's in Store for Selecta (SELB) This Earnings Season?
by Zacks Equity Research
In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.
Selecta's (SELB) Gene Therapy Gets Rare Pediatric Disease Tag
by Zacks Equity Research
The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.
Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -153.13% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Selecta Biosciences (SELB) Q2 Earnings & Sales Miss Estimates
by Zacks Equity Research
Selecta Biosciences (SELB) miss estimates for earnings and revenues in the second quarter of 2020.
What Awaits Selecta Biosciences (SELB) This Earnings Season?
by Zacks Equity Research
In the absence of any marketed drugs, investor focus is likely to be on Selecta Biosciences' (SELB) lead pipeline candidate, SEL-212 on the second-quarter conference call.
Is Selecta Biosciences (SELB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SELB) Outperforming Other Medical Stocks This Year?
Selecta Biosciences (SELB) in Focus: Stock Moves 7.4% Higher
by Zacks Equity Research
Selecta Biosciences (SELB) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Is Selecta Biosciences (SELB) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SELB) Outperforming Other Medical Stocks This Year?
Is Selecta (SELB) Stock a Solid Choice Right Now?
by Zacks Equity Research
Selecta (SELB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Selecta Biosciences Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Selecta Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.
Will Selecta Biosciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Selecta Biosciences.
Selecta Biosciences Enters Oversold Territory
by Zacks Equity Research
Selecta Biosciences, Inc. (SELB) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Selecta Biosciences (SELB) In Focus: Stock Moves 6.5% Higher
by Zacks Equity Research
Selecta Biosciences (SELB) moved big last session, as its shares jumped over 6% on the day.
Selecta Biosciences (SELB) Enters Oversold Territory
by Zacks Equity Research
Selecta Biosciences, Inc. (SELB) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Selecta Biosciences (SELB): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Selecta Biosciences (SELB) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.